|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7157584||AZURITY||Benzimidazole derivative and use thereof|| |
(1 year, 7 months from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7572920||AZURITY||Benzimidazole derivative and use as a II receptor antagonist|| |
(1 year, 3 months from now)
|US9066936||AZURITY||Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent|| |
(4 years from now)
Edarbi is owned by Azurity.
Edarbi contains Azilsartan Kamedoxomil.
Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.
Edarbi was authorised for market use on 25 February, 2011.
Edarbi is available in tablet;oral dosage forms.
Edarbi can be used as treatment of hypertension.
The generics of Edarbi are possible to be released after 26 March, 2028.
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic